Stem Cell Therapy for Pre and Post Organ Transplantation

There has been ample of preclinical and animal studiesshowing efficacy and safety of using various cells, such as stem cells or T regulatory cells, after transplantation for tissue repair, immunosuppression or tolerance induction. And there has been a significant progress recently using cell therapy in solid organ transplantation in small clinical trials. Recent results have been promising and using cell therapy in solid organ transplantation seems feasible and safe. 

Cell-based therapies have been proposed as innovative approaches to repair marginal organs, minimizing ischemia reperfusion injury (IRI) and induce immune tolerance in solid organ transplantation. The hope is that administration of cells with immunoregulatory properties to transplant recipients could tip the balance between effector and regulatory pathways, ultimately promoting the potential of the host immune system to control the immune response to the allograft. In particular, bone marrow cells, hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), and T regulatory cells (Treg) are emerging as a promising cell therapy in clinical transplantation.